EntryPoint Capital LLC Purchases New Position in Twist Bioscience Co. (NASDAQ:TWST)

EntryPoint Capital LLC acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,040 shares of the company's stock, valued at approximately $420,000.

Other institutional investors have also recently modified their holdings of the company. Arizona State Retirement System increased its holdings in Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after buying an additional 219 shares during the period. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares during the period. Hillsdale Investment Management Inc. increased its stake in shares of Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after acquiring an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Twist Bioscience by 2.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock worth $734,000 after purchasing an additional 363 shares during the last quarter. Finally, US Bancorp DE lifted its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the period.

Remove Ads

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $1.22 during trading on Friday, hitting $40.36. The company had a trading volume of 559,838 shares, compared to its average volume of 940,446. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -11.94 and a beta of 2.15. The stock has a fifty day simple moving average of $45.15 and a two-hundred day simple moving average of $45.33. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same period in the previous year, the firm posted ($0.75) EPS. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. On average, research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Robert W. Baird lifted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Insider Buying and Selling

In other news, Director Robert Chess sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now directly owns 16,641 shares in the company, valued at $832,050. The trade was a 23.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the company's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares of the company's stock, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,799 shares of company stock worth $1,593,944. 3.01% of the stock is owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.